Replies to post #47105 on MMRGlobal, Inc. (fka MMRF)

[EZ2]

Patents Quickly Becoming Invaluable Assets to World's Technology Giants


Five Star Equities Provides Stock Research on Yahoo! Inc. and Eastman Kodak Company


04/11 08:20 AM

--------------------------------------------------------------------------------

NEW YORK, NY -- (MARKETWIRE) -- 04/11/12 -- The Technology Sector patent wars have started to heat up once again. Booming markets for smartphones and tablet computers have caused patents for these devices to become invaluable assets to the world's technology giants. Five Star Equities examines the outlook for companies in the Technology Sector and provides equity research on Yahoo! Inc. (YHOO:$14.99,00$-0.11,00-0.73%) and Eastman Kodak Company (EKDKQ:$0.28,00$-0.01,00-3.45%) .

Access to the full company reports can be found at:

www.FiveStarEquities.com/YHOO
www.FiveStarEquities.com/EKDKQ

On Monday Microsoft agreed to purchase 800 patents from AOL (TWX:$35.41,00$-0.62,00-1.72%) for over $1 billion, which works out to be a price tag of $1.3 million per patent. The high prices companies are paying reflect the major role patents are playing in the business and legal strategies of major tech companies. Patent claims and counter claims are being filed almost every day in courtrooms around the world. "Microsoft (MSFT:$30.47,00$-0.63,00-2.03%) is increasing its arsenal, even if it is expensive," said James E. Bessen, a patent expert and lecturer at the Boston University School of Law.

"The analogy people use is that this is like nuclear (weapons) stockpiling, where companies have been acquiring patents to deter each other from attacking," Timothy Lee from the Cato Institute said. "Now we've gone from a cold war to an actual war where companies are suing each other."

Five Star Equities releases regular market updates on the Technology Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Yahoo! Inc. (YHOO:$14.99,00$-0.11,00-0.73%) , the premier digital media company, recently announced that its Board appointed three new independent directors, effective April 5, 2012: John D. Hayes, Executive Vice President and Chief Marketing Officer of American Express Company (AXP:$56.18,00$-0.98,00-1.71%) ; Peter Liguori, former Chief Operating Officer of Discovery Communications, Inc. (DISCA:$49.74,00$-1.08,00-2.13%) and former Chairman and President of Entertainment of Fox Broadcasting Network; and Thomas J. McInerney, the outgoing Chief Financial Officer of IAC/InterActiveCorp (IACI:$47.61,00$-0.88,00-1.81%) .

Eastman Kodak Company (EKDKQ:$0.28,00$-0.01,00-3.45%) has announced that it has entered into an agreement with Shutterfly (SFLY:$26.84,00$-1.37,00-4.86%) , a leading Internet-based social expression and personal publishing service, for the proposed sale of certain assets of its KODAK Gallery on-line photo services business for $23.8 million. The terms of the agreement include the transfer of Gallery customer accounts and images in the U.S. and Canada to Shutterfly (SFLY:$26.84,00$-1.37,00-4.86%) . The agreement comprises the initial, stalking horse bid in a Court-supervised auction process under Section 363 of the U.S. Bankruptcy Code that will ensure the maximization of value for the assets.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.FiveStarEquities.com/disclaimer


Contact:
Five Star Equities
Email Contact

[EZ2]

The International Myeloma Foundation Says Pomalidomide, an Important New Drug for Patients, Has Been Submitted for FDA Approval

Accelerated Review Could Make the Drug Available to Patients by Year End

04/27 08:02 AM

--------------------------------------------------------------------------------

NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)-- The International Myeloma Foundation (IMF) – the oldest and largest foundation dedicated to improving the life and care of myeloma patients – said a new drug for multiple myeloma has been submitted to the US Food and Drug Administration for approval. The drug, called pomalidomide, developed by CELGENE, would be used for patients with multiple myeloma who no longer respond to other therapies and would join the important, yet limited, number of drugs approved to fight this cancer. No new drugs have been approved for multiple myeloma in nearly six years.

“A proven new drug such as pomalidomide would fill the void left when patients have stopped responding to available drugs,” said Susie Novis, President and Co-founder of the IMF. “New drugs such as REVLIMID® and VELCADE® have dramatically changed the course of treatment, giving patients longer remissions with a good quality of life. Because we don’t have a cure yet, patients can work their way through the available treatments, which is why new options like pomalidomide are so important.”

Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affects the production of red cells, white cells and stem cells and can damage bone. It is growing in numbers and affecting increasingly younger people. Although multiple myeloma was once “a rare disease of the elderly,” the IMF has recently been contacted by a patient in her early twenties and another still in his teens. Pomalidomide is an oral drug that attacks the cancer in multiple ways, fighting the cells directly, as well as stimulating the immune system. Clinical trials have demonstrated that pomalidomide is beneficial even in patients who have already stopped responding to multiple treatments.

“Pomalidomide is derived from the same science that brought us REVLIMID, but it is a distinct drug that can play an important role for patients,” said Brian G.M. Durie, M.D., Chairman and Co-founder of the IMF. “Patients who have stopped responding to REVLIMID can have a sustained response and benefit from pomalidomide. This is a powerful drug, and once approved we expect it to play a key role in our tireless fight against myeloma.”

Another new drug, called carfilzomib, was also submitted to the FDA at the end of last year and is undergoing review. Like pomalidomide, it works in many patients who have stopped responding to other treatments, but each drug works by a different mechanism of action. Other new developments include the introduction of injectable VELCADE to replace the intravenous infusion, and REVLIMID maintenance, which involves using drugs long-term, instead of stopping after a fixed number of cycles. Pomalidomide will also be submitted for approval in Europe later this year.

ABOUT THE INTERNATIONAL MYELOMA FOUNDATION

Celebrating its 21st anniversary, the International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 215,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses on four key areas: research, education, support, and advocacy. To date, the IMF has conducted more than 250 educational seminars worldwide, maintains a world-renowned hotline, and established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients. The IMF can be reached at (800) 452-CURE (2873). The global website is www.myeloma.org.


Source: International Myeloma Foundation